Onsdag 24 Juni | 22:53:58 Europe / Stockholm
Svenska | English
Kursutveckling under dagen för detta pressmeddelande (SEK).
Est. tid*
2027-02-12 08:00 Bokslutskommuniké 2026
2026-10-28 08:00 Kvartalsrapport 2026-Q3
2026-08-20 08:00 Kvartalsrapport 2026-Q2
2026-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2026-05-06 - Årsstämma
2026-04-30 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-08-12 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2025-05-06 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-08-01 - Extra Bolagsstämma 2024
2024-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2024-05-06 - Årsstämma
2024-05-06 - Kvartalsrapport 2024-Q1
2024-02-26 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-24 - X-dag ordinarie utdelning DICOT 0.00 SEK
2023-05-23 - Årsstämma
2023-05-19 - Kvartalsrapport 2023-Q1
2023-02-27 - Bokslutskommuniké 2022
2023-01-09 - Extra Bolagsstämma 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning DICOT 0.00 SEK
2022-05-24 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-28 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-10-06 - Extra Bolagsstämma 2021
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning DICOT 0.00 SEK
2021-05-25 - Årsstämma
2021-05-17 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-23 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning DICOT 0.00 SEK
2020-05-26 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-22 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning DICOT 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Dicot Pharma utvecklar läkemedelskandidaten LIB-01 vilket förväntas bli ett potensläkemedel för att behandla erektionssvikt och tidig utlösning. Verkningstid och färre biverkningar är huvudsakliga önskade egenskaper. Dicots huvudstrategi är att under utvecklingen av LIB-01 löpande utvärdera industriella partnerskap för att ta läkemedelskandidaten fram till kommersialisering. Bolaget är baserat i Uppsala.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7

2026-06-24 11:00:00

Uppsala, Sweden, June 24, 2026. Dicot Pharma AB’s rights issue of units, for which the subscription period ended on June 4, 2026 (the "Rights Issue"), has now been registered with the Swedish Companies Registration Office and paid subscribed units ("BTU") will be replaced by shares and warrants of series TO 7. The last day of trading in BTU on Nasdaq First North Growth Market is June 25, 2026, and the first day of trading in warrants of series TO 7 is July 1, 2026.

The last day of trading in BTU is June 25, 2026 and the conversion date for BTU is June 29, 2026. The new shares and warrants are expected to be credited to each shareholder’s VP account/custody account on or around July 1, 2026. The first day of trading in warrants of series TO 7 is July 1, 2026 and the last day of trading is May 20, 2027.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.

Attachments
Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden